{
    "cancer_info": {
        "cancer_name": "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "CBC with differential",
            "Comprehensive metabolic panel (including LDH)",
            "Serum immunoglobulin levels (IgG, IgA, IgM)",
            "Flow cytometry (peripheral blood/bone marrow/lymph node)",
            "FISH cytogenetics: del(13q), trisomy 12, del(11q), del(17p), complex karyotype",
            "Molecular testing: TP53 mutation (exons 4-9), IGHV mutational status, NOTCH1, SF3B1, BIRC3 mutations",
            "Excisional lymph node biopsy (for Richter transformation)",
            "PET-CT (SUVmax >10 for Richter transformation suspicion)",
            "Contrast-enhanced CT (chest/abdomen/pelvis)",
            "Bone marrow aspirate/biopsy",
            "Hepatitis B screening: HBsAg, anti-HBc, anti-HBs",
            "Direct Antiglobulin Test (DAT)",
            "Beta-2-microglobulin measurement",
            "CpG-Stimulated Karyotype",
            "Next-generation sequencing (NGS) for BTK (C481), PLCG2, BCL2 mutations"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Rai Stage 0 (Low Risk)",
            "risk_group": "Favorable Risk (mutated IGHV, del(13q) sole abnormality)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Without del(17p)/TP53 mutation",
                    "plan_name": "BTK inhibitor monotherapy",
                    "plan_details": "Acalabrutinib or Zanubrutinib (continuous therapy)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Without del(17p)/TP53 mutation",
                    "plan_name": "Venetoclax + Obinutuzumab",
                    "plan_details": "Fixed-duration (12 cycles)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Rai Stages I-IV / Binet A-C",
            "risk_group": "High Risk (del(17p)/TP53 mutation)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "With del(17p)/TP53 mutation",
                    "plan_name": "BTK inhibitor monotherapy",
                    "plan_details": "Acalabrutinib or Zanubrutinib (continuous therapy)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "With del(17p)/TP53 mutation",
                    "plan_name": "Venetoclax monotherapy",
                    "plan_details": "Continuous therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "Prior BTK inhibitor exposure",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line therapy",
                    "patient_subgroup": "Progression on covalent BTKi",
                    "plan_name": "Venetoclax-based therapy",
                    "plan_details": "Venetoclax ± Rituximab/Obinutuzumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "BTKi-resistant with BTK C481 mutations",
                    "plan_name": "Pirtobrutinib",
                    "plan_details": "Non-covalent BTK inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed/Refractory Disease",
            "risk_group": "Prior Venetoclax exposure",
            "treatment_plans": [
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "Progression on Venetoclax",
                    "plan_name": "BTK inhibitor",
                    "plan_details": "Acalabrutinib or Zanubrutinib (if naïve)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Subsequent therapy",
                    "patient_subgroup": "BCL2 mutation (Gly101Val)",
                    "plan_name": "CAR T-cell therapy",
                    "plan_details": "Lisocabtagene maraleucel (for ≥2 prior lines)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        },
        {
            "staging_criteria": "Richter Transformation (DLBCL)",
            "risk_group": "Clonally related DLBCL",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Untreated transformation",
                    "plan_name": "VR-CHOP",
                    "plan_details": "Venetoclax + R-CHOP",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other recommended"
                },
                {
                    "treatment_line": "Salvage therapy",
                    "patient_subgroup": "Refractory disease",
                    "plan_name": "CAR T-cell therapy",
                    "plan_details": "Lisocabtagene maraleucel",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "del(17p)/TP53 mutation: Predicts chemoimmunotherapy resistance; mandates targeted therapy (BTK/BCL-2 inhibitors)",
            "Unmutated IGHV: Shorter PFS with chemoimmunotherapy; better outcomes with BTK inhibitors",
            "Complex Karyotype (≥3 abnormalities): Independent predictor of inferior overall survival",
            "BTK C481 mutation: Mediates resistance to covalent BTK inhibitors (ibrutinib/acalabrutinib/zanubrutinib)",
            "BCL2 Gly101Val mutation: Primary mechanism of resistance to Venetoclax",
            "NOTCH1 mutation: Predicts higher risk of Richter transformation",
            "PLCG2 mutation: Contributes to covalent BTK inhibitor resistance",
            "SF3B1 mutation: Associated with disease progression"
        ]
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：慢性淋巴细胞白血病／小淋巴细胞淋巴瘤.txt"
}